Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Adult Solid Neoplasm|Inflammatory Breast Carcinoma|Male Breast Carcinoma|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer
Interventions: DRUG: Capecitabine|DRUG: Docetaxel|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|DRUG: Tipifarnib
Sponsor: National Cancer Institute (NCI)